The BHLSI B2B Program has developed a sophisticated life sciences network and an outstanding B2B team of experts in Haifa/Israel and Boston/Massachusetts.

 

  What Experts are Saying About the BHLSI…

"I would like to express our sincere appreciation for your efforts in establishing the CJP BHLSI initiative at Boston. We believe that this initiative could pave the way for Israeli start-up companies to be successful in raising funds and cooperate with local entities and professionals in the Boston area and the USA.

We find that conducting the sessions during the 3 days at Boston achieved

    1.    Fast introduction to VCs and angels

    2.   Highly valuable feedback for the company

    3.   Introduction to top professionals "

Shai Levanon
CEO
Rcadia Medical Imaging

---

"We truthfully appreciate the advices the participating Investors addressed to us during the conference. It was extremely helpful for us, as a young company, to learn and benefit from them.

As all the other participants we were very impressed by BHLSI wonderful organization and the efficiency of the program. In addition, we appreciate very much the grate effort you are investing for creating a unique opportunities to Israeli companies. "

Eliav Thar
CEO
VETERIX Ltd

---

“The CJP Boston-Haifa Life Sciences Initiative serves as an important bridge to fostering collaborations with  the potential to contribute to mutual growth and success between Massachusetts and Greater Haifa biomedical companies. By facilitating relationships with partners and key resources, this initiative can help produce the highest quality deal-flow and investment opportunities to groups such as the Keiretsu Forum -- an investment community of accredited private equity investors, venture capitalists and corporate/institutional investors that invest in high-quality, diverse investment opportunities – whereby both communities can benefit.”

Henry Kay
Co-Chair Life Sciences Committee
Keiretsu Forum

---

"Israeli biotechnology and device companies are developing cutting-edge technologies that offer novel solutions to some of the most complex problems facing society today, ranging from healthcare to homeland security.   With the tremendous intellectual capital, innovation that exists among Israeli scientists and entrepreneurs, Israeli life science companies can provide a unique pipeline of research and products to Massachusetts .  By assisting entrepreneurs in the early stages of corporate development, the CJP Boston-Haifa Life Sciences Initiative (BHLSI) can effectively leverage its network to assist   entrepreneurs & companies with their business and investment strategies in order to prevent common mistakes – and to facilitate entry into the US marketplace. Many of us in the Boston community are committed to sharing our expertise in order to enhance this potential for success."

Hillel Bachrach
Former President & CEO, Orex CR (as of March 2005 sold to Kodak)
Former President, Odin Medical Technologies
Co-Founder, ESC Medical Systems (Lumenis)

---

"The Boston-Haifa Life Sciences Initiative can play an important role in helping to facilitate Israel 's life sciences sector by collaborating closely with academic, industry, government and community organizations in Boston . Further, we can help Israeli life science companies by providing the testing and development platform through  collaboration with our newly established   Brigham Advanced Thoracic Surgical Innovation   Center  . Good ideas and hard work generate progress.  What we can do at the Brigham and Women's Hospital is provide an access to a unique platform for further incubation and development of these ideas in a manner that is profitable to all."

Raphael Bueno, MD
Associate Chief, Division of Thoracic Surgery
Director, Thoracic Surgery Residency Program
Brigham and Women's Hospital
Associate Professor of Surgery
Harvard Medical School

---

"Like Israel , Massachusetts is a leading center for biotechnology, nanotechnology and medical device companies.  For that reason, locating in Massachusetts offers access to the United State's most concentrated venture capital community and one of the most educated, innovative and productive workforces in the world.  We are also home to some of the world's finest universities, medical schools, hospitals and research facilities.  These factors, in conjunction with our industry base, directly contribute to Massachusetts ' commanding position in the global drug and device pipeline, allowing us to offer the keys to success in life sciences' research and development.  Massachusetts is also the industry location of choice with nearly 500 life science businesses representing one of the world's largest concentrations of biotech, pharmaceutical & medical device companies.  Not only is Massachusetts known as the birth place of many life science companies, it has also become the recognized location for investment by external companies that want to access our world-leading innovation economy." 

Tom Finneran 
President, Massachusetts Biotechnology Council

---

"The combined strengths of the Boston and Haifa biomedical communities are uniquely poised to develop these important potentially life saving therapies.  Boston and Haifa are home to many of the leading academic and industry biomedical research centers.  The sharing of technology and research ideas in this setting is a vital element in developing programs that extend from the laboratory bench to commercialization to successful patient therapy."

David Avigan, MD
Director, Bone Marrow Transplantation/Hematological Malignancies
Assistant Professor of Medicine, Harvard Medical School   

---

"From my perspective, the activities of the Boston-Haifa Life Scienes Initiative (BHLSI)  are critical to ensuring high level collaborations between Boston 's extraordinary life sciences community and the superb inventors and entrepreneurs in Israel , Haifa . The Harvard Clinical Research Unit (HCRI) has been extremely supportive of my efforts to secure business in Israel and help Israeli companies obtain FDA approval for their technologies in the U.S.   As a leading academic research organization in the field of cardiovascular clinical trials, HCRI always seeks to be at the forefront of new technology development, advising companies in this space about how to approach the FDA and ensuring high quality execution of their clinical trials.  We are proud to have worked with several Israeli companies thus far and hope to be able to add value to BLSI-affiliated companies in this way."

Mordecai Kramer
Director, Business Development
Harvard Clinical Research Institute

---

"In view of the unique combination between research, education, clinical activity and industry in Haifa , the Greater Haifa region offers an unprecedented opportunity for the life and medical science fields.  A relationship between Boston and Haifa through the Boston-Haifa Life Sciences Initiative (BHLSI) can play a major role to enhance growth and success of  this sector. The Boston community has a lot to contribute and I welcome future interactions along these lines. The Haifa and Boston communities together have an unmatched strength in the biomedical sciences that can shape up the regions vision and provide a message to the world in these areas."

Rafi Beyar, MD, DSc
Director, Division of Invasive Cardiology, Rambam Medical Center
Coordinator, the Cardiovascular Center, The Rambam Medical Center
Sarah and Dr Phillip Gottlieb Chair in Medicine and Biomedical Engineering.
Immediate past Dean, the Rappaport Faculty of Medicine, Technion

---

"The strategy of building enduring and constructive relationships between Massachusetts and Israel/Boston and Haifa provides a real opportunity for Israeli companies, academic institutions and government research bodies (such as hospitals) to increase their chances of successfully utilizing and commercializing their human capital and proprietary knowledge.In my view, and based on my experience, Israel's human capital and highly advanced scientific abilities are one of its most valuable resources and assets.In order live up to its potential, Israel's superb knowledge infrastructure should be complimented by a well designed set of policies, such as in the fields of intellectual property, investment climate, and regulatory frameworks, as well as by professional support in the fields of management and marketing. I believe that the Boston-Haifa Life Sciences Initiatiave (BHLIS) provides these exact tools and is therefore crucial to Israel life-science industries at this time."

Dr. Meir Perez Pugatch, MSc., PhD
University of Haifa , School of Public Health
IP Policy and Commercialisation of Knowledge Assets

---

"The Boston-Haifa Life Sciences Initiative (BHLS) offers tremendous potential for the Israeli and Boston healthcare communities. Israel is known to spawn leading edge biotechnology advances and medical device innovation. However, accessing the technology in a pre-packaged, predictable and investable manner is many times elusive. With Technion and other universities in the Haifa area known for developing new life science related technology there is great potential for systematic fostering of alliances between the medical entrepreneurial and the venture communities of Haifa and Boston."

Darren Black
SV Life Sciences

---

“The Israeli life sciences sector is known to be among the most innovative and advanced in terms of scientific and technological research and product development. The City of Haifa’s symbiotic relationship with the City of Boston shares a somewhat similar reputation of scientific and technological excellence, thus enhancing the potential for joint opportunities and success. The ability of the Boston-Haifa Life Sciences Initiative (BHLSI) to make connections with angel investors, VCs, strategic alliance partners and distributors is important to help Israeli companies achieve success. As an angel investor I am pleased to be part of the BHLSI and to share my experience and network to maximize this potential.”

Don Perrin
Cambridge Business Advisors